SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-010756
Filing Date
2023-03-30
Accepted
2023-03-30 08:00:59
Documents
15
Period of Report
2023-03-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20230329.htm   iXBRL 8-K 66881
2 EX-10.1 sndx-ex10_1.htm EX-10 280017
3 EX-99.1 sndx-ex99_1.htm EX-99 18593
4 GRAPHIC img199102934_0.jpg GRAPHIC 14374
  Complete submission text file 0000950170-23-010756.txt   547093

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sndx-20230329_pre.xml EX-101.PRE 10229
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sndx-20230329_lab.xml EX-101.LAB 13916
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sndx-20230329.xsd EX-101.SCH 2463
9 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20230329_htm.xml XML 4869
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

IRS No.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 23777192
SIC: 2834 Pharmaceutical Preparations